RxDoctor Payments Data

Kevin Martinez, MD

Interventional Pain Medicine · Metairie, LANPI 1700800828

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $214 and has fallen 76.4% since, to $50 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in LA, where the typical reported total is $4,761.

$363in general payments, 2019–2025

Across 15 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$71
  • Boston Scientific$64
  • ALON Medical Technology$51
  • Virtus Pharmaceuticals LLC$34
  • Nevro Corp.$31
  • Pfizer$25
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$363 in reported general payments places this provider in the 5th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$50,779
Medicare patients
171
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine11$4,383
Xtampza ErOxycodone Myristate12$4,317
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen129$1,950
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen68$1,719
Fentanyl13$1,139
Cyclobenzaprine Hcl ErCyclobenzaprine Hcl11$1,105
Gabapentin80$828
Tramadol Hcl74$686
Pregabalin30$347
Oxycodone Hcl13$197
Methocarbamol19$90
Eszopiclone12$85

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →